Scarica l'app Stockscreener
1.11
0.00%
0.00
Precedente Chiudi:
$1.11
Aprire:
$1.19
Volume 24 ore:
579.44K
Relative Volume:
0.86
Capitalizzazione di mercato:
$58.24M
Reddito:
$21.05M
Utile/perdita netta:
$-89.22M
Rapporto P/E:
-0.6201
EPS:
-1.79
Flusso di cassa netto:
$-64.50M
1 W Prestazione:
+15.29%
1M Prestazione:
-47.89%
6M Prestazione:
-23.45%
1 anno Prestazione:
-76.73%
Intervallo 1D:
$1.065
$1.19
Intervallo di 1 settimana:
$0.94
$1.19
Portata 52W:
$0.91
$4.9399
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Nome
Tscan Therapeutics Inc
Settore
Industria
Telefono
857-399-9500
Indirizzo
830 WINTER STREET, WALTHAM
Confronta TCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.11 | 62.99M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-05-16 | Iniziato | BTIG Research | Buy |
| 2024-05-13 | Iniziato | Needham | Buy |
| 2023-06-22 | Iniziato | Wedbush | Outperform |
Tscan Therapeutics Inc Borsa (TCRX) Ultime notizie
How TScan Therapeutics Inc. stock reacts to oil pricesJuly 2025 Reactions & Community Driven Trade Alerts - moha.gov.vn
Is TScan Therapeutics Inc a good long term investmentStock Liquidity Analysis & Free Tools to Find Winning Stocks - earlytimes.in
Is TScan Therapeutics Inc. stock dividend yield sustainableTrade Exit Report & Daily Technical Stock Forecast Reports - moha.gov.vn
TScan Therapeutics Approves Key Employee Retention Program - TipRanks
[8-K] TScan Therapeutics, Inc. Reports Material Event | TCRX SEC FilingForm 8-K - Stock Titan
Cluey Ltd Launches $4.5 Million Entitlement Offer - The Globe and Mail
Tscan Therapeutics Inc (TCRX) is looking forward to a strong quarter - Setenews
Reversal indicators forming on TScan Therapeutics Inc. stockProfit Target & Consistent Profit Alerts - newser.com
Is TScan Therapeutics Inc. stock positioned well for digital economyTrade Ideas & Daily Oversold Bounce Ideas - newser.com
Applying chart zones and confluence areas to TScan Therapeutics Inc.2025 Pullback Review & Reliable Price Breakout Alerts - newser.com
Is TScan Therapeutics Inc. building a consolidation baseJuly 2025 Closing Moves & Safe Capital Growth Stock Tips - newser.com
How TScan Therapeutics Inc. stock performs in high volatility markets2025 Market Outlook & Expert Curated Trade Setups - newser.com
TScan Therapeutics (NASDAQ:TCRX) Cut to Equal Weight at Morgan Stanley - Defense World
Equities Analysts Issue Forecasts for TCRX FY2025 Earnings - Defense World
Best data tools to analyze TScan Therapeutics Inc. stockJuly 2025 Macro Moves & Daily Growth Stock Tips - newser.com
How TScan Therapeutics Inc. stock reacts to global recession fears2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com
HC Wainwright Cuts TScan Therapeutics (NASDAQ:TCRX) Price Target to $7.00 - Defense World
Should you wait for a breakout in TScan Therapeutics Inc.Weekly Risk Summary & Scalable Portfolio Growth Methods - newser.com
How TScan Therapeutics Inc. stock performs in rate cut cyclesWeekly Trade Review & Real-Time Stock Movement Alerts - newser.com
Using data filters to optimize entry into TScan Therapeutics Inc.2025 Earnings Impact & Technical Pattern Recognition Alerts - newser.com
Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight - MarketScreener
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials By Investing.com - Investing.com Canada
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials - Investing.com India
HC Wainwright & Co. Maintains TScan Therapeutics (TCRX) Buy Recommendation - Nasdaq
Is TScan Therapeutics Inc. still worth holding after the dipQuarterly Investment Review & Weekly Breakout Stock Alerts - newser.com
Technical signs of recovery in TScan Therapeutics Inc.Weekly Market Outlook & Accurate Technical Buy Alerts - newser.com
TScan Therapeutics Draws Analyst Optimism Despite Growing Losses - Finimize
Applying sector rotation models to TScan Therapeutics Inc.Quarterly Portfolio Summary & Low Volatility Stock Recommendations - newser.com
TScan Therapeutics Reports Increased Revenue Amid Rising Losses - The Globe and Mail
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates - sharewise.com
Published on: 2025-11-12 17:29:17 - newser.com
Tscan Therapeutics earnings beat by $0.06, revenue topped estimates - Investing.com Canada
What technical models suggest about TScan Therapeutics Inc.’s comebackWeekly Investment Report & Community Trade Idea Sharing - newser.com
TScan Therapeutics, Inc. Q3 Loss Increases, But Beats Estimates - Nasdaq
TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
TScan Therapeutics Q3 revenue jumps - MarketScreener
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
TScan (NASDAQ: TCRX) secures FDA agreement on TSC-101 pivotal design; runway to 2027 - Stock Titan
Tscan Therapeutics Inc Azioni (TCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.45%
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):